Because of the tumor-targeted agonism, FcγRIIB-dependent TNFRSF agonistic antibodies would be better tolerated due to diminished activity in circulation and normal tissues where FcγRIIB and TNFRSF rarely are present in sufficient density. This evidence concerns the gene FCGR2B and neoplasm.